Immunosuppressive drugs in renal transplantation

Authors

  • Rohit K. Singh Department of Pharmacology, Patna Medical College, Patna, Bihar, India
  • Ajit Kishor Department of Pharmacology, Patna Medical College, Patna, Bihar, India
  • Dev R. Rishu Department of Pharmacology, Patna Medical College, Patna, Bihar, India
  • Rashmi Asha Department of Pharmacology, Patna Medical College, Patna, Bihar, India
  • Keshav K. Sinha Department of Pharmacology, Patna Medical College, Patna, Bihar, India
  • Rani I. Sinha Department of Pharmacology, Patna Medical College, Patna, Bihar, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20230405

Keywords:

Immunosuppressive agents, Kidney transplant, Induction therapy, Maintenance therapy

Abstract

A kidney transplant, sometimes known as a renal transplant, is the treatment of choice for kidney failure at end stage renal disease (ESRD). The renal transplant surgery is followed by a lifetime course of immunosuppressive agents, divided into initial induction phase and later maintenance phase. It is seen that the risk of acute rejection is maximum in the initial months after transplantation (induction phase) and then reduces later (maintenance phase). In induction phase there is use of high-intensity immunosuppression immediately after transplantation, when the risk of rejection is maximum and then the dose reduced for long- term therapy. The main challenge in the renal transplantation community is long- term transplant survival. Long-term graft loss is mainly due to acute and chronic graft rejection, and also due to complications of immunosuppressive therapy. Currently, there is triple therapy as conventional immunosuppressive protocol: a calcineurin inhibitor, an antimetabolite agent, and a corticosteroid. The main aim of development of new immunosuppressive agents is not only improvement of short- term outcomes but also to increase the long- term graft survival by less nephrotoxicity, and minimal side-effects.

References

Kasper DL, Fauci AS, Hauser S, et at. Harrison’s Principles of Internal Medicine. 21st ed vol. 1, New York: McGraw Hill; 2021. p.2325.

G. Guerra, G. Ciancio, J.J. Gaynor, A. Zarak, R. Brown, L. Hanson, J. Sageshima, D. Roth, L. Chen, W. Kupin, L. Toreros, P. Ruiz, A.S. Livingstone, G.W. Burke, 3rd Randomized trial of immunosuppressive regimens in renal transplantation, J. Am. Soc. Nephrol. 22 (2011) 1758–1768.

A. Gondos, B. Döhler, H. Brenner, G. Opelz. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes, Transplantation 95 (2013) 267–274. 4. W. Jadström, B.-.G. Ericzon, P.F. Halloran, W.O. Bechstein, G. Opelz, D. Serón, J, et al. Advancing transplantation: New questions, new possibilities in kidney and liver transplantation, Transplantation 101 (2017) S1–S41.

Opelz G, Dohler B. Lymphomas after solid organ transplantation: a Collaborative Transplant Study report. Am J Transplant. 2004; 4: 222-30.

Nickeleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309-15.

Grino JM, Alsina J, Sabater R, Castelao AM, Gil-Vernet S, et al. Antilymphoblast globulin, cyclosporin and steroids in Cadaveric renal transplantation. Transplantation 49: 1114-1117, 1990.

Norman DJ, Barry JM, Bennett WM, Munson JL, Meyer M, et al. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses. Transplantation Proceedings. 23: 1052-1054, 1991.

Walker RG, d’Apice AJF. Azathioprine and steroids. In Morris (Ed.) Kidney transplantation: principles and practice. 3rd ed., pp. 319-341, WB Saunders, Philadelphia, 1988.

Griffin PJA, Salaman JR. Long-term results of cyclosporine monotherapy in kidney transplantation. Transplantation Proceedings. 23: 992-993, 1991.

Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002;2:19-24.

U.S. Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, Md.: National Institutes of Health, National Institutes of Diabetes & Digestive Kidney Diseases, 2003.

Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.

Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004;4:384-9.

Fritsche L, Einecke G, Fleiner F, Dragun D, Neumayer HH, Budde K. Reports of large immunosuppression trials in kidney transplantation: room for improvement. Am J Transplant 2004;4:738-43.

Hariharan S, McBride MA, Cohen EP. Evolution of endpoints for renal transplant outcome. Am J Transplant 2003;3:933-41.

Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004;4:561-8.

Fredericks S, Holt DW, MacPhee IA. The pharmacogenetics of immunosuppression for organ transplantation: a route to injournal editorial fellow dividualization of drug administration. Am J Pharmacogenomics 2003;3:291-301.

MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74:1486-9.

Auchincloss H Jr. In search of the elusive holy grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001;1:6-12.

Downloads

Published

2023-02-22

How to Cite

Singh, R. K., Kishor, A., Rishu, D. R., Asha, R., Sinha, K. K., & Sinha, R. I. (2023). Immunosuppressive drugs in renal transplantation. International Journal of Basic & Clinical Pharmacology, 12(2), 303–312. https://doi.org/10.18203/2319-2003.ijbcp20230405

Issue

Section

Review Articles